Q-omics provides the consensus-scored BFSP2 profile across patient tissues and cancer cell-line models. BFSP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BFSP2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, BFSP2 RNA expression shows 13,935 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where BFSP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BFSP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BFSP2 survival associations across molecular data types. BFSP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BFSP2 RNA expression–survival associations across cancer types. High BFSP2 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, BLCA, CESC, LUAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BFSP2 RNA expression.
This table summarizes BFSP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BFSP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BFSP2 shows lower tumor expression in COAD, THCA, KIRC and KIRP and higher tumor expression in LUAD and BRCA. The COAD box plot shows higher BFSP2 RNA expression in normal versus tumor tissue (log2 FC = −0.351, t-test p < 0.001).
This table shows molecular features associated with BFSP2 in patient tissues and cancer cell lines. In patient samples, BFSP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BFSP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
